Anticoagulant Management of Mechanical Heart Valve Patients During Perioperative Surgery: A Case Report
DOI:
https://doi.org/10.26911/theijmed.2023.08.04.01Abstract
Background: Patients with mechanical heart valves require lifelong oral anticoagulation. It will be a dilemma if a patient with a mechanical heart valve has surgery. This case report aims to discuss how to interrupt oral anticoagulants and bridging therapy in patients with mechanical heart valves who will be undergoing non-cardiac surgery.
Case Report: A 26-year-old pregnant woman, G1P0A0, aterm with a mechanical mitral valve, will have elective Sectio Caesarian Transperitonealis (SCTP) surgery and Intra Uterine Device (IUD) insertion. The patient had a history of mitral valve replacement surgery (MVR) in 2014 and was routinely treated with 4 mg of warfarin at night. From the examination, blood pressure was 120/80 mmHg, heart rate was 90 beats per minute, and pulse rate was 90 beats per minute. The ECG examination found sinus rhythm with 1st-degree atrioventricular block, right axis deviation, 90 beats per minute, and left atrial enlargement. We decided to have oral anticoagulant interruption and bridging therapy by stopping warfarin three days before surgery. When the international normalized ratio (INR) falls <2, patients are given heparin injections (UFH) with an APTT target of 1.5-2.0 times from basic APTT. When the patient was about to be operated on, UFH was stopped 6 hours before surgery and resumed 12 hours after surgery. Warfarin was given one day postoperatively. Patients were adjusted to the dose of UFH according to the target. This patient had no thromboembolic events or bleeding before, during, or after surgery. The patient was allowed to be an outpatient and was given home therapy with Warfarin 5 mg at night.
Results: We report a case of a 26-year-old female patient with a mechanical mitral valve who was going to undergo elective SCTP surgery and an IUD insertion. Patients at high risk of thrombo¬embolism due to surgery with a high risk of bleeding. Bridging therapy was performed using UFH. In the perioperative period, the patient did not experience thromboembolic events, and bleeding before, during, and after surgery could be well controlled.
Conclusion: Perioperative management of patients with mechanical heart valves must be done carefully. Interruption of oral anticoagulants should be carefully considered considering the risk of thromboembolism and bleeding during the perioperative period. Guidelines recommend that in patients with mechanical heart valves, anticoagulation interruption for minor surgeries is avoided. Whereas in patients with major surgery, it is necessary to do bridging therapy with fast-acting anticoagulants such as UFH or LMWH.
Keywords: mechanical heart valve, anticoagulant interruption, perioperative, bridging therapy
Correspondence: Trisulo Wasyanto. Department of Cardiology and Vascular Medicine, Faculty of Medicine, Sebelas Maret University / Dr. Moewardi Hospital. Jl. Kol. Sutarto 132, Surakarta 57126, Central Java, Indonesia. Email: trisulo.wasyanto@staff.uns.ac.id. ORCID ID: 0000-0001-9900-0497. Mobile: +62811294225.
References
Baumgartner H, Falk V, Lancellotti P, Lansac E, Rosenhek R, Sjögren J, Vahanian A, et al. (2017). ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 38: 273991.
Biteker M, Tekkesin AI, Can MM, Dayan A, Ilhan E, Türkmen FM (2012). Outcome of noncardiac and nonvascular surgery in patients with mechanical heart valves. Am J Cardiol. 110: 5627.
Chan WS, Anand S, and Ginsberg JS (2000). Anticoagulation of pregnant women with mechanical heart valves: A systematic review of the literature. Arch Intern Med. 160: 1916.
Daniels PR, McBane RD, Litin SC, Ward SA, Hodge DO, Dowling NF, Heit JA, et al. (2009). Periprocedural anticoagulation management of mechanical heart valve patients. Thromb Res; 124: 3005.
Douketis JD, Spyropoulos AC, Kaatz S, et al. (2012). Bridging anticoagulation: Is it needed when warfarin is interrupted around the time of a surgery or procedure? Circulation. 125: e4968.
Douketis JD, Spyropoulus AC, Spencer FA, Michael M, Jaffer AK, Eckman MH, Dunn AS, et al. (2012). Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 141: e326S50S.
Douketis JD, Spyropoulos AC, Kaatz S, Becker RC. 2015. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Eng J Med. 373(9): 82333.
Eijgenraam P, ten Cate H, and ten CateHoek AJ. 2014. The practice of bridging anticoagulation: guideline adherence and risk factors for bleeding. Neth J Med. 72(3): 15764.
Fleiser LA, Fleischmann KE, Aurbach AD, Bernason SA, Beckman JA, Bozkurt B, DavilaRoman VG, et al. 2014. ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. J Am Coll Cardiol. 64(22): e77137.
Hassouna A and Allam H. 2014. Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: A meta-analysis. Interact Cardiovasc Thorac Surg. 18: 797806.
Keeling D, Baglin T, Taite C, Watson H, Perry D, Baglin C, Kitchen S, et al. (2011). Guidelines on oral anticoagulation with warfarin fourth edition. Br J Haematol. 154(3): 31124.
Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. (2012). National trends in oral anticoagulant use in the United States, 2007 to 2012. Circ Cardiovasc Qual. 5: 61521.
Kristensen SD, Knuuti J, Saraste A, Anker S, Hert SD, Ford I, GonzalezJuanatey R, et al. (2014). ESC/ESA Guidelines on noncardiac surgery: cardiovascular assessment and management. Eur Heart J. 35: 2383431.
Moesker MJ, de Groot JF, Damen NL, Bijsterveld NR, Twisk JWR, Huisman MV, Wagner C, et al. (2019). Guideline compliance for bridging anticoagulation use in vitamin-K antagonist patients; practice variation and factors associated with noncompliance. Throm J. 17:15.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, O’Gara PT, et al. (2014). AHA/ACC Guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 63(22): e57185.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, O’Gara PT, et al. (2017). 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 70(2): 25289.
Rechenmacher SJ and Fang JC. 2015. Bridging anticoagulation. J Am Coll Cardiol. 66(12): 392403.
RegitzZagrosek V, RoosHesselink JW, Bauersachs J, Bonis MD, Lung B, Johnson MR, Kintscher U, Kranke P, et al. (2018). ESC Guideline for the management of cardiovascular diseases during pregnancy. Eur Heart J. 00: 183.
Shaikh SI, Kumari RV, Hegade G, Marutheesh M. 2017. Perioperative considerations and management of patients receiving anticoagulants. Anesth Essays Res. 11(1): 1016.
Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. (2012). Periprocedural heparin bridging in patients receiving vitamin K antagonists: a systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 126: 16309.
Tafur AJ, McBane R, Wysokinski WE, Litin S, Daniels P, Slusser J, Hodge D, Beckman G, et al. (2012). Predictors major bleeding in periprocedural anticoagulation management. J Thromb Haemost. 10(2): 2617.
Tafur AJ and Douketis J (2018). Perioperative management of anticoagulant and antiplatelet therapy. Heart. 104. 14617.
Tan CW, Wall M, Rosengart TK, Rosengart TK, Ghanta RK (2019). How to bridge? Management of anticoagulation in patients with mechanical heart valves undergoing noncardiac surgical procedures. J Thorac Cardiovascular Surg. 158(1): 2003.
Van Hagen IM, RoosHesselink JW, Ruys TP, Merz WM, Goland S, Gabriel H, Lelonek M, et al. (2015). Pregnancy in women with a mechanical heart valve: Data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 132: 13242.
Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. 2012. Antithrombotic and thrombolytic therapy for valvular heart disease: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 141(2): e576S600S.
Wysokinski WE and McBane RD II (2012). Periprocedural bridging management of anticoagulation. Circulation. 126: 48690.
Xu Z, Fan J, Luo X, Zhang W, Ma J, Lin Y, Ma S, et al. (2016). Anticoagulation regimens during pregnancy in patients with mechanical heart valves: A systematic review and meta-analysis. Can J Cardiol. 32: 1248.e11248.e9
